Company profile
Aviva Bio
Re-Engineering a Proven Hormone Through Modern Science
- Industry
- Biotechnology Research
- Employees
- 3
- Headquarters
- Concord, MA
- Founded
- 2025
- LinkedIn followers
- 510
- Office locations
- 1
Aviva Bio company summary
Aviva Bio is a company in the Biotechnology Research industry, headquartered in Concord, MA, founded in 2025. On LinkedIn the company has around 3 employees and 510 followers.
What technology does Aviva Bio use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Aviva Bio
Aviva Bio is a clinical-stage biotechnology company focused on advancing hormone-based medicine. We aim to unlock the potential of hormone therapies through precision drug design, targeting patient populations with significant unmet medical needs. Historically, the clinical use of testosterone has been constrained because it converts into estrogen through a process called aromatization. Aviva Bio’s lead therapeutic program, AVA-291 (d3-Testosterone), is designed to preserve androgen activity while resisting aromatization. d3-Testosterone: Re-engineered Testosterone The Problem Standard testosterone therapy can convert into estradiol through aromatization. This conversion has been associated with clinical risks such as: --Gynecomastia in men (aka "man boobs") --Increased breast cancer risk in women These risks have historically limited the clinical development of testosterone-based treatments. The Gap Testosterone plays an important physiological role in: --Libido --Muscle mass --Energy levels --Metabolic health --Overall quality of life However, safety concerns associated with aromatization have constrained the development of therapies based on testosterone. The Solution d3-Testosterone (d3-T) is an investigational androgen therapy designed to retain the beneficial effects of testosterone while resisting aromatization. The compound is structurally identical to testosterone except that certain hydrogen atoms are replaced with deuterium, a naturally occurring isotope. This molecular modification is designed to: --Maintain androgen receptor activity --Prevent conversion into estradiol --Enable safer androgen therapy across different clinical contexts.
Where is Aviva Bio located?
Aviva Bio lists 1 location.
Compare companies similar to Aviva Bio
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Aviva Bio aviva-bio.com | Biotechnology Research | 3 | 2025 | Concord, MA |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Aviva Bio
What does Aviva Bio do?
Aviva Bio is a clinical-stage biotechnology company focused on advancing hormone-based medicine. We aim to unlock the potential of hormone therapies through precision drug design, targeting patient populations with significant unmet medical needs. Historically, the clinical use of testosterone has been constrained because it converts into estrogen through a process called aromatization. Aviva Bio’s lead therapeutic program, AVA-291 (d3-Testosterone), is designed to preserve androgen activity while resisting aromatization. d3-Testosterone: Re-engineered Testosterone The Problem Standard testosterone therapy can convert into estradiol through aromatization. This conversion has been associated with clinical risks such as: --Gynecomastia in men (aka "man boobs") --Increased breast cancer risk in women These risks have historically limited the clinical development of testosterone-based treatments. The Gap Testosterone plays an important physiological role in: --Libido --Muscle mass --Energy levels --Metabolic health --Overall quality of life However, safety concerns associated with aromatization have constrained the development of therapies based on testosterone. The Solution d3-Testosterone (d3-T) is an investigational androgen therapy designed to retain the beneficial effects of testosterone while resisting aromatization. The compound is structurally identical to testosterone except that certain hydrogen atoms are replaced with deuterium, a naturally occurring isotope. This molecular modification is designed to: --Maintain androgen receptor activity --Prevent conversion into estradiol --Enable safer androgen therapy across different clinical contexts.
How many employees does Aviva Bio have?
Aviva Bio has around 3 employees on LinkedIn.
Where is Aviva Bio headquartered?
Aviva Bio is headquartered in Concord, MA.
When was Aviva Bio founded?
Aviva Bio was founded in 2025.
Build a lead list from companies like Aviva Bio
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.